Combined Effects of Drugs: Synergism
Protein Complexes with Interchangeable Parts
Drug-Receptor Bonds
Covalently Linked Protein Regulators
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Victor Hernandez-Olmos1,2, Jonathan Vincent Patzke3, Caroline E Stone3
1Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
New dual inhibitors targeting USP25 and USP28 deubiquitylases (DUBs) were developed by merging AZ1 and vismodegib structures. These potent compounds show promise as chemical probes and therapeutic candidates for diseases like cancer.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: